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(here were 411 presentations related to vascular disease,
ypertension, and prevention during the American College
f Cardiology 2006 Scientific Sessions, including the results
f the Study to Evaluate the Effect of Rosuvastatin on
ntravascular Ultrasound-Derived Coronary Atheroma Bur-
en (ASTEROID), numerous substudies of the Compari-
on of Amlodipine versus Enalapril to Limit Occurrences of
hrombosis (CAMELOT) trial, and a number of new trials
valuating risk factors and treatments. These presentations
ere selected from a total of 1,278 abstracts submitted to
he program committee.
LOPIDOGREL
ust before Labor Day weekend in 2004, former U.S.
resident Bill Clinton presented with chest pain to a local
ospital. Angiography showed extensive multivessel coro-
ary artery disease, but his coronary artery bypass surgery
as reportedly delayed several days because he had taken
lopidogrel during his initial hospitalization. One of the
bstracts from the Scripps Clinic sheds some light on how
e may address this clinical scenario in the future.
Drs. Matthew Price and Garrett Wong studied the effects
f clopidogrel 75 mg administered daily to 44 volunteers for
mean of 13 days after a loading dose (1). The percent
nhibition of platelet aggregation mediated by the P2Y12
eceptor was measured by point-of-care testing using the
erifyNow assay (Accumetrics, San Diego, California).
latelet aggregation was measured before the initial dose,
4 h after the last dose, and 4 days thereafter. A substantial
roportion of subjects had low platelet inhibition at each
ime point; but interestingly, at day 5, two of the subjects
till had persistent platelet inhibition. Clearly, further study
s needed to investigate the utility of point-of-care testing to
etter identify patients on clopidogrel who can either
ndergo surgery earlier or who may need to wait even longer
efore surgical intervention.
In a study using Pravastatin or Atorvastatin Evaluation
nd Infection Therapy–Thrombolysis In Myocardial
nfarction-22 (PROVE IT–TIMI-22) patients, Schweiger
t al. (2) sought to determine whether high-dose atorvasta-
in attenuated the efficacy of clopidogrel, given that both
torvastatin and clopidogrel are metabolized through the
ytochrome p450 3A4 system. In this evaluation of 4,161
atients with acute coronary syndrome (ACS), each subject
eceived either high-dose atorvastatin 80 mg daily or
From the *Ciccarone Preventive Cardiology Center, Johns Hopkins University
chool of Medicine, Baltimore, Maryland; and the †Department of Medicine,e
ardiovascular Division, University of Pennsylvania School of Medicine; Philadel-
hia, Pennsylvania.tandard-dose pravastatin 40 mg daily; 3,038 of 4,161
atients were receiving clopidogrel at study entry, whereas
,123 were not. At both 30 days and 2 years there was no
ifference in the incidence of death or myocardial infarction
mong those on statin therapy when analyzed by the presence
r absence of clopidogrel (Table 1). Thus, the combination of
igh-dose atorvastatin and clopidogrel produced no meaning-
ul interaction or reduction in efficacy of treatment.
The addition of clopidogrel to aspirin has been shown to
e more beneficial than aspirin alone in a number of
econdary prevention studies. For example, trials evaluating
lopidogrel in acute ST-segment elevation myocardial in-
arction include the Clopidogrel as Adjunctive Reperfusion
herapy–Thrombolysis In Myocardial Infarction-28
CLARITY–TIMI-28) trial (3) and the Clopidogrel and
etoprolol in Myocardial Infarction Trial/Second Chinese
ardiac Study (COMMIT/CCS-2) (4). In ACS patients,
vailable data include the Clopidogrel in Unstable Angina
o Prevent Recurrent Events (CURE) study (5). In the
etting of percutaneous coronary intervention (PCI), we
ave data from the Clopidogrel for Reduction of Events
uring Observation (CREDO) study (6).
At ACC.06, the main results were presented from the
lopidogrel for High Atherothrombotic Risk, Ischemic
tabilization, Management, and Avoidance (CHARISMA)
tudy. The trial involved 15,603 patients 45 years old or
ore who were deemed to be at high risk of atherothrom-
otic events. All subjects were treated with aspirin, and half
ere randomized to once-daily clopidogrel 75 mg (7). The
rimary end point was a composite of myocardial infarction,
troke, or cardiovascular death.
Surprisingly, in the primary prevention group with mul-
iple risk factors, dual-platelet inhibition was associated
ith a trend toward a higher cardiac event rate than therapy
ith aspirin alone (6.6% vs. 5.5%, 95% confidence interval
.91 to 1.59; p  0.20). Conversely, in the much larger
ubgroup with a history of atherothrombosis, the event rates
ere 6.9% in the dual antiplatelet inhibition group and 7.9%
n the aspirin-only group (95% confidence interval 0.77 to
.998; p 0.046) (8). Further cost-effectiveness analyses are
equired to identify any subgroup that may benefit from
ual-antiplatelet therapy in the secondary prevention set-
ing, aside from the standard scenarios of post-PCI or
ost-ACS for 9 to 12 months.
HE CAMELOT SUBSTUDIES
he CAMELOT study looked at the effect of amlodipine
10 mg) and enalapril (20 mg) on cardiovascular (CV)
vents in normotensive coronary artery disease (CAD)
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ACC 2006 Annual Session Highlights June 6, 2006:D3–8atients (n  1,991) (9). Treatment with amlodipine was
ssociated with a reduction in the composite end point of
V events compared with placebo; this was largely driven by
Abbreviations and Acronyms
ACS  acute coronary syndrome
ASTEROID  A Study to Evaluate the Effect
of Rosuvastatin on
Intravascular Ultrasound-
Derived Coronary
Atheroma Burden
CAD  coronary artery disease
CAMELOT  Comparison of Amlodipine vs.
Enalapril to Limit Occurrences
of Thrombosis
CHARISMA  Clopidogrel for High
Atherothrombotic Risk,
Ischemic Stabilization,
Management, and
Avoidance
CLARITY  Clopidogrel as Adjunctive
Reperfusion Therapy
COMMIT/CCS-2  Clopidogrel and Metoprolol
in Myocardial Infarction
Trial/Second Chinese Cardiac
Study
CREDO  Clopidogrel for Reduction of
Events During Observation
CURE  Clopidogrel in Unstable
Angina to Prevent Recurrent
Events
CV  cardiovascular
HDL  high-density lipoprotein
hsCRP  high-sensitivity C-reactive
protein
IMT  intima-media thickness
IVUS  intravascular ultrasound
LDL  low-density lipoprotein
Lp(a)  lipoprotein(a)
MACE  major adverse cardiac events
MESA  Multi-Ethnic Study of
Atherosclerosis
MetS  metabolic syndrome
NHANES  National Health And
Nutrition Examination Survey
PCI  percutaneous coronary
intervention
PROVE IT–TIMI-22  Pravastatin or Atorvastatin
Evaluation and Infection
Therapy–Thrombolysis
In Myocardial Infarction-22
PWV  pulse wave velocity
TAV  total atheroma volume
able 1. The PROVE IT–TIMI-22 Trial: Statins With or With
Outcome
Atorvastatin/Clopidogrel
(n  1,542)
Atorvastatin/
No Clopidogrel
(n  557)
0-day death/MI 1.1% 1.8% 0.
-year death/MI 7.7% 9.9% 0.eprinted with permission (2).
MI  myocardial infarction.reduction in coronary revascularization and hospitalization
rom angina. These reductions were not seen with enalapril
ompared with placebo, despite a similar reduction in blood
ressure.
In a post-hoc analysis of CAMELOT study subjects who
ere treated with any statin, amlodipine was associated with
44% relative reduction in major adverse cardiac events
MACE) versus placebo (25% vs. 17%; p 0.002) and a 26%
isk reduction versus enalapril (22% vs. 17%; p  0.03) (10).
he investigators concluded that treatment with amlodipine
0 mg for two years reduced the risk of MACE compared with
lacebo and enalapril in normotensive patients treated with a
tatin. There was a suggestion of synergy related to the
ombination of amlodipine and atorvastatin (p  0.029).
Another study by the same group looked at 363 patients
ith diabetes mellitus, 822 patients with metabolic syn-
rome (MetS), and 350 patients with impaired fasting
lucose (11). Among patients with diabetes mellitus, amlo-
ipine reduced MACE compared with enalapril (hazard
atio  0.58; p  0.04), and the results were similar for
atients with MetS; amlodipine reduced the incidence of
ACE significantly compared with placebo (hazard ratio 
.62; p  0.02) and enalapril (hazard ratio  0.59; p 
.008). Amlodipine also reduced CV events in normoten-
ive patients with impaired fasting glucose compared with
lacebo (Table 2). We do not know whether the results
ould have been different if the angiotensin-converting
nzyme inhibitor enalapril had been given twice per day or
erhaps if a more lipophilic angiotensin-converting enzyme
nhibitor had been used instead of enalapril.
In an economic analysis of CAMELOT study data,
ormotensive patients with CAD treated with amlodipine
ad fewer CV hospitalizations and lower associated costs
12). This seems to address most of the concerns first raised
n the mid-1990s regarding short-acting calcium channel
lockers, which were associated with higher event rates in
atients with acute coronary syndromes; apparently, longer-
cting calcium channel blockers are safe and effective in
educing CV events.
The CAMELOT study investigators also looked at the
ffect of beta-blockers on progression of coronary athero-
clerosis using intravascular ultrasound (IVUS), which was
erformed on a single artery at baseline and after two years
f treatment with amlodipine, enalapril, or placebo (13).
he change in total atheroma volume (TAV) was compared
or those treated with and without beta-blockade, with
esults adjusted for study treatment, blood pressure, and lipids.
lopidogrel
Pravastatin/Clopidogrel
(n  1,496)
Pravastatin/
No Clopidogrel
(n  566) p Interaction p
1.3% 1.1% 0.70 0.27
9.7% 10.7% 0.33 0.68out C
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June 6, 2006:D3–8 ACC 2006 Annual Session Highlightseta-blockers were associated with significantly lower progres-
ion of TAV (p  0.03) compared with patients not on
eta-blocker therapy who had significantly greater increases in
AV. This observational analysis suggests that beta-blockers
ay slow CAD progression as part of their cardioprotective
ffects in the secondary prevention setting.
Another CAMELOT substudy suggests that normal
lood pressure (125 mm Hg systolic) also may slow CAD
rogression compared with either high normal or high
ystolic blood pressure (14). Investigators used IVUS of a
ingle artery; progression of coronary disease was measured
s the change in TAV. The mean blood pressure in all
ubjects was 127/76 mm Hg, and the change in TAV was
igher in patients with a systolic blood pressure 140 mm
g (p  0.001) and in patients with a systolic reading of
able 2. Effect of Amlodipine and Enalapril on Major Adverse C
isease in the CAMELOT Trial
Subgroup/Outcome
Amlodipine Enalapril Placebo
Event Rate
(%)
Event Rate
(%)
Event Ra
(%)
iabetes mellitus
(n  363)
19% 30% 29%
etabolic syndrome
(n  822)
15% 23% 23%
mpaired fasting glucose
(n  350)
12% 18% 23%
eprinted with permission (11).igure 1. Use relationship between mean low-density lipoprotein cholesterol
dapted with permission from JAMA, March 13, 2006 [e pub ahead of print]25 to 140 mm Hg (p  0.02). Indeed, although the TAV
ncreased in both of these groups, there was a small decrease
n TAV among those with a systolic pressure125 mm Hg.
he results support the epidemiologic evidence that there is
continuous risk reduction with lower blood pressure levels.
hus, in addition to aggressive lipid-lowering therapy, we
hould also advocate aggressive blood pressure control for
ur patients with coronary heart disease.
HE ASTEROID TRIAL
he goal of the ASTEROID (A Study to Evaluate the
ffect of Rosuvastatin on Intravascular Ultrasound-Derived
oronary Atheroma Burden) trial was to assess whether
ntensive statin therapy could actually regress coronary
therosclerosis (15). This was a prospective, open-label,
ac Events in Normotensive Patients With Coronary Artery
Amlodipine
vs. Placebo
Amlodipine
vs. Enalapril
Enalapril
vs. Placebo
Hazard
Ratio p Value
Hazard
Ratio p Value
Hazard
Ratio p Value
0.62 0.067 0.58 0.043 1.06 0.796
0.62 0.015 0.59 0.008 1.05 0.779
0.47 0.018 0.64 0.192 0.75 0.339ardi
teand median percent atheroma volume in intravascular ultrasound trials.
, Copyright © 2006 American Medical Association. All rights reserved.
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ACC 2006 Annual Session Highlights June 6, 2006:D3–8ulticenter, blinded-end-points trial involving motorized
VUS pullback to assess the atheroma burden at baseline
nd after 24 months. At the end of two years, 349 patients
ad evaluable serial IVUS studies. All patients received
osuvastatin 40 mg per day with no comparator group. The
rimary end point included change in percent atheroma
olume and change in nominal atheroma volume in a selected
0-mm (most diseased) subsegment of the study artery.
After treatment, a 53% mean reduction in low-density
ipoprotein (LDL) cholesterol levels was observed. On-
reatment mean LDL decreased from 130 to 61 mg/dl (p 
.001), with high-density lipoprotein (HDL) cholesterol
alues increasing 15% from 43 to 49 mg/dl (p  0.001).
fter 24 months, the mean change in percent atheroma
olume was 1% compared with baseline (p  0.001). The
hange in atheroma volume of the most-diseased 10-mm
ubsegment was 6 mm3 compared with baseline (p 
.001). Moreover, there was a 7% median reduction com-
ared with baseline in the secondary efficacy measure of
hange in TAV. Interestingly, the coronary artery lumen
ross-sectional area did not change.
Although it may be hypothesized that the increase in
DL was responsible for this regression, the r2 value in this
nalysis was 0.95 (Fig. 1), suggesting that the very low LDL
evels achieved alone may account for this modest regression
n percent atheroma volume.Figure 2. Comparison of diabetic and nondiabetic plaques. RepETABOLIC SYNDROME
n a study of global risk assessment, investigators at the
niversity of California, Irvine, led by Dr. Nathan D.
ong, used the National Health And Nutrition Examina-
ion Survey (NHANES) database to calculate the Framing-
am risk score for individuals with MetS (16). Among all
atients with MetS, one-half were classified at intermediate
o high risk for CHD, and one-half were classified at low
isk. These low-risk subjects would not qualify for aspirin
herapy, and they would not qualify for lipid-lowering
herapy unless their LDL level was 160 mg/dl. Of note,
mong those classified at intermediate to high risk, the
ajority were men or African American.
The investigators suggested that given the growing rec-
gnition of MetS as an indicator of increased CV risk,
reater risk assessment using measurements of subclinical
therosclerosis or measurement of high-sensitivity
-reactive protein (hsCRP) may be useful in selected people
ith MetS to more appropriately target treatment intensity.
lthough the Framingham risk score classifies many
iddle-aged people with MetS as low risk, clinicians need
o motivate these individuals to improve their lifestyle habits
nd consider further risk stratification to determine whether
hey are suitable candidates for aspirin and lipid-lowering
herapy.rinted with permission from Purushothaman et al. (20).
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June 6, 2006:D3–8 ACC 2006 Annual Session HighlightsInvestigators from Japan evaluated the impact of MetS
nd diabetes in long-term outcomes after PCI in 748
onsecutive patients, who were characterized based on the
resence or absence of MetS (17). They found that patients
ith MetS, but not necessarily with frank diabetes, were at
he highest risk (p 0.0001). Clearly, the presence of MetS
t discharge after PCI is an indicator of high risk, and
linicians should place a greater emphasis on improving the
ietary and exercise habits of MetS patients, including
ncreased efforts to reduce obesity.
The theme of seemingly high-risk patients not being
dentified by traditional risk assessment emerged again in
he German Heinz Nixdorf Recall study, which is being
onducted in parallel to the ongoing Multi-Ethnic Study of
therosclerosis (MESA) in the U.S. The Heinz Nixdorf
ecall study group is a population-based unselected
uropean cohort. The investigators sought to determine
ow risk assessment may be affected by the extent of
nflamed plaque burden, which they defined as a combi-
ation of elevated hsCRP and coronary calcium score
Agatston method) (18).
Many clinicians have come to realize that if a woman is
ounger than 65 years old, it is nearly impossible for her to
each the 10% 10-year Framingham risk score that would
ake her eligible for aspirin or lipid-lowering therapy (if her
DL-cholesterol is 160 mg/dl). In this analysis, the
nvestigators defined risk as being elevated if the calcium
core was100 and hsCRP was3 mg/dl, or if the calcium
core was 400 and hsCRP was at least 1 mg/dl. They
oncluded that the extent of subclinical CAD inflammatory
ctivity may be significantly underestimated in selected
ramingham low-risk patients. Individuals with a high
alcium score and elevated hsCRP levels also tend to have
ther components of MetS; these patients specifically need
ore thorough investigation from their physicians, as well
s more lifestyle modification, and consideration for earlier
nstitution of aspirin and lipid-lowering therapy.
OVEL AGENTS/NOVEL RISK FACTORS
mong several ongoing studies considering the effects on
ardiac events of thiazolidinediones, a group from Japan
eported on their efforts to see whether pioglitazone slowed
rogression of atherosclerosis by measuring intima-media
hickness (IMT) of the common carotid artery and arterial
tiffness by the brachial-to-ankle pulse wave velocity (PWV)
19). Both IMT and PWV decreased significantly in pa-
ients taking pioglitazone, although the improvement in
MT and PWV did not correlate well with levels of
emoglobin A1c. They concluded that pioglitazone may
educe arterial wall thickness and stiffness in a manner that
ay be partly independent of glucose lowering.
Cardiovascular researchers from the Mount Sinai School
f Medicine hypothesized that sustained injury may induce
reparative process including increased collagen synthesisnd accelerated CAD progression in diabetics (20). Inves-igators obtained lipid-rich plaques from the aorta at
utopsy from those with and without diabetes, and com-
ared levels of inflammation, neovascularization, in-
raplaque hemorrhage, and reparative collagen. The levels of
nflammation, neovascularization, and reparative collagen
ere increased significantly in plaques taken from patients
ith diabetes. The levels of type III collagen also were
ncreased in plaques with intraplaque hemorrhage (Fig. 2)
nd correlated with the total microvessel content. The
nvestigators concluded that increased inflammation and
eovascularity in diabetes is associated with a reparative
rocess that is mediated by type III collagen and likely
ontributes to aggressive plaque progression in diabetes.
Using data from the Women’s Health Study, which
ollowed up 27,000 healthy women for 10 years, Suk Danik
t al. (21) attempted to assess the future risk of CV events
ased on baseline lipoprotein(a) [Lp(a)] levels. They found
hat median levels of Lp(a) and the overall distribution of
p(a) differed among women in whom CV disease did and
id not develop. A median level of 66 mg/dl in the top
uintile was associated with a 60% higher likelihood of
eveloping CV disease than those in the first quintile, in
hich the median level was only 2 mg/dl (p  0.0001).
hey concluded that only very high levels of Lp(a) were
ssociated with an increased risk of CV disease in their
redominantly Caucasian female cohort.
eprint requests and correspondence: Dr. Roger S. Blumenthal,
iccarone Preventive Cardiology Center, Blalock 524C, Johns
opkins Hospital, 600 North Wolfe Street, Baltimore, Maryland
1287. E-mail: rblument@jhmi.edu.
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